Trastuzumab is a humanized monoclonal antibody that binds to HER-2 with high specificity, preventing the recombination of EGF and HER-2, thereby slowing down cancer cell growth. Studies have also shown that Trastuzumab can reduce the expression of HER-2 on the surface of cancer cells. Additionall...
Trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) is utilized for the treatment of human breast cancer (1, 2), but a complete understanding of how tumor signal transduction is modulated by trastuzumab treatment is lacking. By mining published an...
A trastuzumab is a humanised monoclonal antibody and targets the human epidermal growth factor receptor (HER2) oncoprotein but not associated with chemotherapy. It improves results for all HER2 positive women, regardless of age, hormone...
Monoclonal antibodiesfor HER+ breast cancer such as Herceptin (trastuzumab), Perjeta (pertuzumab), and Margenza (argetuximab) Kinase inhibitorsfor HER2+ breast cancer such as Tykerb (lapatinib), Nerlynx (neratinib), and Tukysa (tucatinib) CDK inhibitorsor ER+ breast cancer such as Ibrance (palboci...
Recent years have witnessed the great progress of targeted cancer therapies; however, for GC patients, only trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2, and ramucirumab, a monoclonal antibody against vascular endothelial growth factor receptor 2, proved to have ...
Isatuximab-irfc (Sarclisa; sanofi-aventis US LLC) is a targeted monoclonal antibody approved for patients with relapsed and refractory multiple myeloma—the second most common blood cancer.1,2 More than 130,000 Americans are affected by multiple myeloma, and approximately 32,000 p...
2 A monoclonal antibody is used for IHC staining of the proliferation-associated nuclear protein Ki-67 in tumor cells to determine the percentage of Ki-67–positive cells among the total population of tumor cells in formalin-fixed paraffin-embedded sections obtained from a core-cut biopsy sample;...
Amplification and overexpression of HER2 is seen in approximately 15% of breast carcinomas and is associated with a poor prognosis [10–14]. Adjuvant therapy using a monoclonal antibody against HER2 protein (trastuzumab) is effective alone and in combination with conventional cytotoxic chemotherapy in...
Trastuzumab is a humanised monoclonal antibody against the extracellular domain of human epidermal growth factor receptor-2 (HER2) and has shown therapeutic benefit in the 15–20% of breast cancer patients who overexpress HER2 with impressive improvements in clinical benefit and survival when added to...
To explore the sensitivity and dynamic range of the Orbitrap Exploris 240 MS, SEC and pH gradient elution cation exchange chromatography (CEX) were employed for the analysis of the class 1 monoclonal antibod...